Pasithea Therapeutics (KTTA) Total Non-Current Liabilities (2021 - 2024)
Pasithea Therapeutics (KTTA) has disclosed Total Non-Current Liabilities for 4 consecutive years, with $163578.0 as the latest value for Q3 2024.
- Quarterly Total Non-Current Liabilities fell 31.81% to $163578.0 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $163578.0 through Sep 2024, down 31.81% year-over-year, with the annual reading at $84366.0 for FY2023, 89.51% down from the prior year.
- Total Non-Current Liabilities hit $163578.0 in Q3 2024 for Pasithea Therapeutics, up from $93272.0 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $1.5 million in Q4 2021 to a low of $57650.0 in Q1 2024.
- Historically, Total Non-Current Liabilities has averaged $547590.1 across 4 years, with a median of $528096.0 in 2021.
- Biggest five-year swings in Total Non-Current Liabilities: skyrocketed 147.21% in 2022 and later tumbled 92.68% in 2024.
- Year by year, Total Non-Current Liabilities stood at $1.5 million in 2021, then crashed by 44.64% to $804207.0 in 2022, then plummeted by 89.51% to $84366.0 in 2023, then surged by 93.89% to $163578.0 in 2024.
- Business Quant data shows Total Non-Current Liabilities for KTTA at $163578.0 in Q3 2024, $93272.0 in Q2 2024, and $57650.0 in Q1 2024.